Subjects: Cost-Benefit Analysis / Titles: CardioMEMS (tm) HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto (tm), Novartis AG) for management of congestive heart failure: effectiveness, value, and value-based price benchmarks : final report - Digital Collections - National Library of Medicine Search Results

Start Over Subjects Cost-Benefit Analysis ✖ Titles CardioMEMS (tm) HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto (tm), Novartis AG) for management of congestive heart failure: effectiveness, value, and value-based price benchmarks : final report ✖

1. CardioMEMS (tm) HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto (tm), Novartis AG) for management of congestive heart failure: effectiveness, value, and value-based price benchmarks : final report

Author(s):: Ollendorf, Daniel A., author
Ollendorf, Daniel A., author
Tarlochan Sandhu, Alexander, author
Chapman, Rick, author
Heidenreich, Paul A., author
Russo, Elizabeth, author
Shore, Karen K., author
Synnott, Patricia, author
Travers, Karin, author
Weissberg, Jed, author
Pearson, Steven D., author
Publication:: [Boston, MA] : Institute for Clinical and Economic Review, December 1, 2015
Subject(s):: Angiotensin II Type 1 Receptor Blockers -- administration & dosage
Antihypertensive Agents -- administration & dosage
Blood Pressure Monitoring, Ambulatory -- instrumentation
Blood Pressure Monitoring, Ambulatory -- methods
Heart Failure -- diagnosis
Heart Failure -- drug therapy
Neprilysin -- administration & dosage
Tetrazoles -- administration & dosage
Valsartan -- administration & dosage
Angiotensin II Type 1 Receptor Blockers -- economics
Antihypertensive Agents -- economics
Cost-Benefit Analysis
Drug Combinations
Drug Costs
Neprilysin -- antagonists & inhibitors
Neprilysin -- economics
Outcome and Process Assessment (Health Care)
Tetrazoles -- economics
Valsartan -- economics
Humans
United States